Tis (in situ)

TIS (Carcinoma In Situ, CIS)

TIS (Tis) stands for Carcinoma In Situ, a high-grade, flat (non-papillary) tumor confined to the urothelium (innermost lining of the bladder). It is classified under the TNM staging system for bladder cancer as:

1. Tis (TaTis): Pure CIS (no invasion).
2. Tis + Ta/T1: CIS coexisting with papillary tumors.

Key Features of CIS

1. Aggressive Nature:
   1. High-grade (HG) by definition.
   2. Not invasive but has a high risk of progression to muscle-invasive disease (~50% if untreated).
2. Microscopic Appearance:
   1. Disorganized, malignant cells limited to the urothelium.
   2. No penetration into the lamina propria or muscle.
3. “Field Effect”:
   1. Often multifocal (scattered across the bladder).
   2. May extend into prostatic urethra or upper tracts.

Clinical Presentation

• Symptoms:
  • Irritative voiding (urgency, frequency, dysuria) – mimics UTI.
  • Hematuria (less common than with papillary tumors).
• Diagnosis Challenges:
  • Invisible on cystoscopy (~30% of cases) → Requires random biopsies + urine cytology.
  • Positive urine cytology (key clue, especially with negative imaging).

Diagnosis

1. Cystoscopy with Blue-Light/NBI (enhances CIS detection).
2. Biopsies:
   1. Targeted (if visible lesions).
   2. Random (if suspicion persists despite normal appearance).
3. Urine Tests:
   1. Cytology (high specificity for HG tumors).
   2. FISH (UroVysion), NMP22 (adjuncts).

Management

First-Line Treatment: BCG Immunotherapy

• Induction: 6 weekly intravesical BCG instillations.
• Maintenance: 3-week courses at 3, 6, 12, 18, 24, 30, and 36 months.
• Response Rates:
  • Complete response (CR) in ~70% initially.
  • ~30–50% progress if BCG fails.

BCG-Unresponsive CIS Options:

1. Pembrolizumab (Keytruda®) – FDA-approved (41% CR rate).
2. Radical Cystectomy – Gold standard for refractory cases.
3. Clinical Trials:
   1. Nadofaragene firadenovec (gene therapy).
   2. Vicinium (antibody-drug conjugate).

Prognosis

• With BCG: 5-year progression-free survival ~60–70%.
• Without Treatment: High risk of progression to T1/T2+ disease.

Why is CIS Dangerous?

• Invisible lesions → Delayed diagnosis.
• High recurrence/progression rates → Requires aggressive surveillance.
• Predictor of poor outcomes if coexists with T1 tumors.

Takeaway

TIS (CIS) is a stealthy, high-risk bladder cancer variant requiring BCG immunotherapy and close monitoring. Early detection and treatment are critical to prevent muscle invasion.

Links